PHASE 1 STUDY EVALUATING HYDROGEL-FORMULATED UC-MSCS ADMINISTERED SUBCUTANEOUSLY IN ADDITION TO STANDARD OF CARE AS A TREATMENT FOR LUPUS NEPHRITIS (ISN-WCN 2026) - Mar 20, 2026 - Abstract #WCN26-AB-8180; Pres time: Mar 28, 2026; 05:30 PM - 06:30 PM; Location: Exhibition Hall/Poster Board No. P609; P1 | "Lupus treatment relies on the use of glucocorticoids and conventional immunosuppressants (e.g. methotrexate, azathioprine, or mycophenolate mofetil) and targeted therapies (e.g. belimumab, anifrolumab, or voclosporin) to control disease activity and prevent relapse...Secondary endpoints include changes from baseline in SLE activity scores, patient-reported QoL measurements and prednisone administrationResults As of Oct...Investigation of the safety and clinical utility of SC-administered hf-UC-MSCs as a treatment for lupus and LN is ongoing. Further conclusions to be based on data collected through Jan., 2026"
Late-breaking abstract • P1 data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|